Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Gastrointestinal Stromal Tumors 71Sarcoma 12Brain Neoplasms 10Gliosarcoma 9Glioblastoma 9Neoplasm Metastasis 6Glioma 6Dermatofibrosarcoma 6Oligodendroglioma 5Central Nervous System Neoplasms 5Astrocytoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Fibrosarcoma 4Chordoma 4Sarcoma, Synovial 3Osteosarcoma 3Neurofibrosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Neoplasms 3Liposarcoma 3Hemangiosarcoma 3Glioma, Subependymal 3Digestive System Neoplasms 3Desmoid Tumors 3Sarcoma, Endometrial Stromal 2Recurrence 2Primary Myelofibrosis 2Piebaldism 2Multiple Myeloma 2Meningioma 2

Interventions

Magnetic Resonance Spectroscopy 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatoses × Imatinib Mesylate × Sarcoma × Clear all
NCT00427583 2012-08-07

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Novartis

Phase 2/3 Terminated
11 enrolled
CNSSarcoma

Neurofibromatoses, Nerve Sheath Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡